

# Dominique Costagliola

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7546987/publications.pdf>

Version: 2024-02-01

534  
papers

30,249  
citations

4146

87  
h-index

7348

152  
g-index

556  
all docs

556  
docs citations

556  
times ranked

21133  
citing authors

#	ARTICLE	IF	CITATIONS
1	Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 713-722.e3.	4.4	9
2	Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 209-221.	9.1	233
3	A new SARS-CoV-2 variant with high lethality poorly detected by RT-PCR on nasopharyngeal samples: an observational study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 298.e9-298.e15.	6.0	13
4	Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1-5.	6.0	15
5	Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 445-454.	2.9	5
6	A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial. <i>Lancet HIV</i> , the, 2022, 9, e79-e90.	4.7	18
7	Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1404-1412.	3.0	25
8	Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer. <i>Cells</i> , 2022, 11, 1015.	4.1	7
9	Increased Production of B-Cell Activating Cytokines and Altered Peripheral B-Cell Subset Distribution during HIV-Related Classical Hodgkin Lymphoma. <i>Cancers</i> , 2022, 14, 128.	3.7	2
10	Coronary Angiographic Features and Major Adverse Cardiac or Cerebrovascular Events in People Living With Human Immunodeficiency Virus Presenting With Acute Coronary Syndrome. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, 101161CIRCINTERVENTIONS122011945.	3.9	3
11	Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 764-765.	9.1	8
12	Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma. <i>Haematologica</i> , 2021, 106, 2233-2241.	3.5	4
13	Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE. <i>Clinical Infectious Diseases</i> , 2021, 73, 195-202.	5.8	8
14	Pharmacological data of a successful 4â€¦daysâ€¦week regimen in HIV antiretroviral therapy (ANRS 162â€¦4D) Tj ETQq0 0 0 rgBT /Over	2.4	4
15	Use of rilpivirine in HIV-1-infected individuals in routine clinical practice from 2012 to 2017 in France. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 467-476.	3.0	3
16	A Comparison of Cell Activation, Exhaustion, and Expression of HIV Coreceptors and Restriction Factors in HIV-1- and HIV-2-Infected Nonprogressors. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 214-223.	1.1	3
17	Prospective evaluation of blood Epsteinâ€¦Barr virus DNA load and antibody profile in HIV-related non-Hodgkin lymphomas. <i>Aids</i> , 2021, 35, 861-868.	2.2	5
18	Chronic use of reninâ€¦angiotensinâ€¦aldosterone system blockers and mortality in COVIDâ€¦19: A multicenter prospective cohort and literature review. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 1141-1158.	1.9	4

#	ARTICLE	IF	CITATIONS
19	An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN- $\beta$ -1a and hydroxychloroquine in hospitalized patients with COVID-19. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1826-1837.	6.0	77
20	COVID-19: individual and herd immunity. <i>Comptes Rendus - Biologies</i> , 2021, 344, 7-18.	0.2	2
21	No need for secondary <i>Pneumocystis jirovecii</i> pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/ $\mu$ L. <i>Journal of the International AIDS Society</i> , 2021, 24, e25726.	3.0	8
22	Can HIV epidemics among MSM be eliminated through participation in preexposure prophylaxis rollouts?. <i>Aids</i> , 2021, 35, 2347-2354.	2.2	3
23	Do people living with HIV face more secondary cancers than general population: From the French CANCERVIH network. <i>Bulletin Du Cancer</i> , 2021, 108, 908-914.	1.6	5
24	Hepatitis C virus (HCV) incidence among men who have sex with men (MSM) living with HIV: results from the French Hospital Database on HIV (ANRS CO4-FHDH) cohort study, 2014 to 2017. <i>Eurosurveillance</i> , 2021, 26, .	7.0	7
25	CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. <i>Clinical Infectious Diseases</i> , 2021, 73, 50-59.	5.8	18
26	Revealing HIV epidemic dynamics and contrasting responses in two WHO Eastern European countries: insights from modeling and data triangulation. <i>Aids</i> , 2021, 35, 675-680.	2.2	3
27	Epidemiology of Kaposi's Sarcoma. <i>Cancers</i> , 2021, 13, 5692.	3.7	20
28	Prevalence of tubulopathy and association with renal function loss in HIV-infected patients. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 607-615.	0.7	7
29	Propensity Score Analysis of Artesunate Versus Quinine for Severe Imported <i>Plasmodium falciparum</i> Malaria in France. <i>Clinical Infectious Diseases</i> , 2020, 70, 280-287.	5.8	18
30	Recurrence and Occurrence of Kaposi's Sarcoma in Patients Living With Human Immunodeficiency Virus (HIV) and on Antiretroviral Therapy, Despite Suppressed HIV Viremia. <i>Clinical Infectious Diseases</i> , 2020, 70, 2435-2438.	5.8	17
31	In situ BCL2 expression is an independent prognostic factor in HIV-associated DLBCL, a LYMPHOVIR cohort study. <i>British Journal of Haematology</i> , 2020, 188, 413-423.	2.5	5
32	Potential lung cancer screening outcomes using different age and smoking thresholds in the ANRS CO4 French Hospital Database on HIV cohort. <i>HIV Medicine</i> , 2020, 21, 180-188.	2.2	7
33	Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV. <i>Aids</i> , 2020, 34, 599-608.	2.2	7
34	Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV. <i>Journal of Infectious Diseases</i> , 2020, 221, 516-522.	4.0	7
35	Increased Prevalence of Neurocognitive Impairment in Aging People Living With Human Immunodeficiency Virus: The ANRS EP58 HAND 55-70 Study. <i>Clinical Infectious Diseases</i> , 2020, 70, 2641-2648.	5.8	19
36	Re-engagement in care of people living with HIV lost to follow-up after initiation of antiretroviral therapy in Mali: Who returns to care?. <i>PLoS ONE</i> , 2020, 15, e0238687.	2.5	4

#	ARTICLE	IF	CITATIONS
37	Favorable outcome of HIV-associated Burkitt lymphoma in the modern combined antiretroviral therapy era. <i>European Journal of Cancer</i> , 2020, 138, 189-192.	2.8	5
38	Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?. <i>Clinical Infectious Diseases</i> , 2020, 71, 2905-2916.	5.8	16
39	Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection. <i>Annals of Internal Medicine</i> , 2020, 172, 297.	3.9	5
40	RE: "EARLY OUTPATIENT TREATMENT OF SYMPTOMATIC, HIGH-RISK COVID-19 PATIENTS THAT SHOULD BE RAMPED UP IMMEDIATELY AS KEY TO THE PANDEMIC CRISIS". <i>American Journal of Epidemiology</i> , 2020, 189, 1443-1444.	3.4	7
41	Trajectories of functioning in bipolar disorders: A longitudinal study in the FondaMental Advanced Centers of Expertise in Bipolar Disorders cohort. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 985-996.	2.3	9
42	Estimating the burden of HIV late presentation and its attributable morbidity and mortality across Europe 2010-2016. <i>BMC Infectious Diseases</i> , 2020, 20, 728.	2.9	46
43	HIV Infection and Long-Term Residual Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2020, 9, e017578.	3.7	12
44	Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3699-3700.	3.0	2
45	Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine. <i>Aids</i> , 2020, 34, 1859-1862.	2.2	10
46	How PrEP users constitute a community in the MSM population through their specific experience and management of stigmatization. The example of the French ANRS-PREVENIR study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 32-39.	1.2	16
47	Cause-specific mortality after diagnosis of cancer among HIV-positive patients: A collaborative analysis of cohort studies. <i>International Journal of Cancer</i> , 2020, 146, 3134-3146.	5.1	14
48	Metabolic Syndrome and Cardiovascular Disease Impacts on the Pathophysiology and Phenotype of HIV-Associated Neurocognitive Disorders. <i>Current Topics in Behavioral Neurosciences</i> , 2020, 50, 367-399.	1.7	11
49	Risk of Severe Bacterial Infection in People Living Human Immunodeficiency Virus Infection in the Combined Antiretroviral Therapy Era. <i>Journal of Infectious Diseases</i> , 2020, 222, 765-776.	4.0	0
50	Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163) Tj ETQq0 0 0 rgBTj/Overlock 10 Tf 50 2	3.0	1
51	Risk Factors for Seborrhoeic Dermatitis Flares: Case-control and Case-crossover Study. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00292.	1.3	6
52	Use of darunavir in HIV-1-infected individuals in routine clinical practice from 2012 to 2016 in France. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3305-3314.	3.0	6
53	Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz330.	0.9	28
54	Factors Influencing the Incubation of an Infectious Form of Creutzfeldt-Jakob Disease. <i>Clinical Infectious Diseases</i> , 2019, 70, 1487-1490.	5.8	1

#	ARTICLE	IF	CITATIONS
55	Access to the waiting list and to kidney transplantation for people living with HIV: A national registry study. <i>American Journal of Transplantation</i> , 2019, 19, 3345-3355.	4.7	17
56	Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2742-2751.	3.0	26
57	Estimates of the HIV undiagnosed population in Belgium reveals higher prevalence for MSM with foreign nationality and for geographic areas hosting big cities. <i>Journal of the International AIDS Society</i> , 2019, 22, e25371.	3.0	12
58	Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial. <i>HIV Medicine</i> , 2019, 20, 202-213.	2.2	7
59	Invasive cervical cancer in HIV-infected women: risk and survival relative to those of the general population in France. Results from the French Hospital Database on HIV (FHDH) Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) CO4 cohort study. <i>HIV Medicine</i> , 2019, 20, 222-229.	2.2	10
60	Trends in the risk of myocardial infarction among HIV-1-infected individuals relative to the general population in France: Impact of gender and immune status. <i>PLoS ONE</i> , 2019, 14, e0210253.	2.5	11
61	Are European HIV cohort data within EuroCoord representative of the diagnosed HIV population?. <i>Aids</i> , 2019, 33, 133-143.	2.2	20
62	Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. <i>American Journal of Epidemiology</i> , 2019, 188, 1569-1577.	3.4	75
63	Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS 163 ETRAL Study. <i>Pharmacotherapy</i> , 2019, 39, 514-520.	2.6	4
64	Routine screening for HIV, hepatitis B virus and hepatitis C virus in individuals undergoing oral and maxillofacial surgery. <i>HIV Medicine</i> , 2019, 20, 353-358.	2.2	1
65	Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals. <i>Statistics in Medicine</i> , 2019, 38, 2428-2446.	1.6	13
66	Impact of Antiretroviral Drugs on Fracture Risk in HIV-Infected Individuals: A Case-Control Study Nested Within the French Hospital Database on HIV (FHDH-ANRS CO4). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 214-223.	2.1	8
67	Epstein-Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern combined antiretroviral therapy era. <i>Aids</i> , 2019, 33, 993-1000.	2.2	9
68	Brief Report: Impact of ART Classes on the Increasing Risk of Cerebral Small-Vessel Disease in Middle-Aged, Well-Controlled, cART-Treated, HIV-Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 547-551.	2.1	7
69	Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1-Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 292-300.	2.1	24
70	Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, e86-e94.	2.1	53
71	Utility of Epstein-Barr Virus Biomarkers in Human Immunodeficiency Virus-related Lymphomas in the Modern Combined Antiretroviral Therapy Era. <i>Clinical Infectious Diseases</i> , 2019, 68, 891-892.	5.8	4
72	Validation and refinement of the clinical staging model in a French cohort of outpatient with schizophrenia (FACE-SZ). <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 92, 226-234.	4.8	12

#	ARTICLE	IF	CITATIONS
73	Risk factors for loss to follow-up, transfer or death among people living with <scp>HIV</scp> on their first antiretroviral therapy regimen in Mali. <i>HIV Medicine</i> , 2019, 20, 47-53.	2.2	10
74	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. <i>Clinical Infectious Diseases</i> , 2018, 66, 893-903.	5.8	105
75	Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 738-747.	3.0	20
76	Revealing geographical and population heterogeneity in <scp>HIV</scp> incidence, undiagnosed <scp>HIV</scp> prevalence and time to diagnosis to improve prevention and care: estimates for France. <i>Journal of the International AIDS Society</i> , 2018, 21, e25100.	3.0	50
77	Risk of Progressive Multifocal Leukoencephalopathy in the Combination Antiretroviral Therapy Era in the French Hospital Database on Human Immunodeficiency Virus (ANRS-C4). <i>Clinical Infectious Diseases</i> , 2018, 67, 275-282.	5.8	17
78	Silent Cerebral Small-Vessel Disease Is Twice as Prevalent in Middle-Aged Individuals With Well-Controlled, Combination Antiretroviral Therapyâ€Treated Human Immunodeficiency Virus (HIV) Than in HIV-Uninfected Individuals. <i>Clinical Infectious Diseases</i> , 2018, 66, 1762-1769.	5.8	48
79	Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 102-109.	2.1	2
80	Targeted HIV Screening in Eight Emergency Departments: The DICI-VIH Cluster-Randomized Two-Period Crossover Trial. <i>Annals of Emergency Medicine</i> , 2018, 72, 41-53.e9.	0.6	21
81	Influence of geographic origin on AIDS and serious non-AIDS morbidity/mortality during cART among heterosexual HIV-infected men and women in France. <i>PLoS ONE</i> , 2018, 13, e0205385.	2.5	1
82	CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era. <i>Aids</i> , 2018, 32, 2605-2614.	2.2	38
83	Susceptibility to Creutzfeldt-Jakob disease after human growth hormone treatment in France. <i>Neurology</i> , 2018, 91, e724-e731.	1.1	5
84	Impact of efavirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens. <i>BMC Infectious Diseases</i> , 2018, 18, 326.	2.9	2
85	Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+. <i>Aids</i> , 2018, 32, 1361-1367.	2.2	14
86	Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	2.2	21
87	Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. <i>International Journal of Epidemiology</i> , 2017, 46, dyw211.	1.9	22
88	Lack of effects of statins on high-density lipoprotein subfractions in HIV-1-infected patients receiving protease inhibitors. <i>Comptes Rendus - Biologies</i> , 2017, 340, 109-113.	0.2	4
89	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. <i>Lancet HIV</i> , 2017, 4, e251-e259.	4.7	10
90	CD4+/CD8 + ratio restoration in long-term treated HIV-1-infected individuals. <i>Aids</i> , 2017, 31, 1685-1695.	2.2	23

#	ARTICLE	IF	CITATIONS
91	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 1316-1326.	5.8	44
92	The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges. <i>Clinical Infectious Diseases</i> , 2017, 64, 1644-1656.	5.8	46
93	Sleep quality, chronotype and metabolic syndrome components in bipolar disorders during the remission period: Results from the FACE-BD cohort. <i>Chronobiology International</i> , 2017, 34, 1114-1124.	2.0	14
94	Outcomes for bipolar patients assessed in the French expert center network: A 2-year follow-up observational study (FondaMental Advanced Centers of Expertise for Bipolar Disorder [FACE-BD]). <i>Bipolar Disorders</i> , 2017, 19, 651-660.	1.9	25
95	Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era. <i>Aids</i> , 2017, 31, 2493-2501.	2.2	51
96	Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 311-318.	2.1	12
97	Predictors of rapid high weight gain in schizophrenia: Longitudinal analysis of the French FACE-SZ cohort. <i>Journal of Psychiatric Research</i> , 2017, 94, 62-69.	3.1	14
98	CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). <i>Clinical Infectious Diseases</i> , 2017, 65, 959-966.	5.8	75
99	Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. <i>HIV Medicine</i> , 2017, 18, 171-180.	2.2	45
100	Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudy. <i>American Heart Journal</i> , 2017, 183, 91-101.	2.7	24
101	Phase II Trial of Lenalidomide in HIV-Infected Patients with Previously Treated Kaposi's Sarcoma: Results of the ANRS 154 Lenakap Trial. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 1-10.	1.1	28
102	Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3172-3176.	3.0	5
103	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2869-2878.	3.0	17
104	Performance of the marginal structural cox model for estimating individual and joined effects of treatments given in combination. <i>BMC Medical Research Methodology</i> , 2017, 17, 160.	3.1	9
105	CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2862-2868.	3.0	5
106	Loss of long-term non-progressor and HIV controller status over time in the French Hospital Database on HIV - ANRS CO4. <i>PLoS ONE</i> , 2017, 12, e0184441.	2.5	19
107	The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment. <i>Aids</i> , 2016, 30, 879-888.	2.2	9
108	Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia. <i>Aids</i> , 2016, 30, 327-330.	2.2	27

#	ARTICLE	IF	CITATIONS
109	Beyond viral suppression of HIV – the new quality of life frontier. <i>BMC Medicine</i> , 2016, 14, 94.	5.5	279
110	Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir. <i>Aids</i> , 2016, 30, 761-769.	2.2	70
111	Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 390-398.	2.1	10
112	When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 214-221.	2.1	22
113	Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. <i>Clinical Infectious Diseases</i> , 2016, 62, 1571-1577.	5.8	52
114	Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naïve patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial). <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2252-2261.	3.0	7
115	Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials. <i>Clinical Infectious Diseases</i> , 2016, 63, 268-280.	5.8	13
116	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw519.	5.8	20
117	HIV-1-RNA in seminal plasma correlates with detection of HIV-1-DNA in semen cells, but not with CMV shedding, among MSM on successful antiretroviral regimens: Table A1.. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3202-3205.	3.0	17
118	Time for a revolution in tracking the HIV epidemic. <i>Lancet HIV</i> , 2016, 3, e337-e339.	4.7	7
119	Switching to Raltegravir From a Virologically Effective Boosted Protease Inhibitor Regimen: A Comparative Effectiveness Analysis From the French Hospital Database on HIV (FHDH-ANRS CO4). <i>Clinical Infectious Diseases</i> , 2016, 63, ciw498.	5.8	5
120	Looking Beyond the Cascade of HIV Care to End the AIDS Epidemic: Estimation of the Time Interval From HIV Infection to Viral Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 348-355.	2.1	39
121	Survival in individuals living with HIV. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 451-454.	3.8	2
122	Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes. <i>Medicine (United States)</i> , 2016, 95, e5133.	1.0	3
123	Influence of geographic origin, sex, and HIV transmission group on the outcome of first-line combined antiretroviral therapy in France. <i>Aids</i> , 2016, 30, 2235-2246.	2.2	8
124	Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA. <i>Aids</i> , 2016, 30, 221-230.	2.2	59
125	Cancers in elite controllers. <i>Aids</i> , 2016, 30, 1852-1855.	2.2	6
126	Prevalence of and Risk Factors for Anal Oncogenic Human Papillomavirus Infection Among HIV-Infected Women in France in the Combination Antiretroviral Therapy Era. <i>Journal of Infectious Diseases</i> , 2016, 213, 1455-1461.	4.0	28



#	ARTICLE	IF	CITATIONS
127	Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression. <i>Clinical Infectious Diseases</i> , 2016, 62, 1297-1303.	5.8	64
128	Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group. <i>Annals of Oncology</i> , 2016, 27, 397-408.	1.2	37
129	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. <i>International Journal of Epidemiology</i> , 2016, 45, 2038-2049.	1.9	43
130	Immunity, inflammation and reservoir in patients at an early stage of HIV infection on intermittent ART (ANRS 141 TIPI Trial). <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 490-496.	3.0	2
131	Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation. <i>Aids</i> , 2015, 29, 857.	2.2	0
132	Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia. <i>Aids</i> , 2015, 29, 853-856.	2.2	5
133	A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control. <i>Aids</i> , 2015, 29, 2003-2007.	2.2	68
134	The impact of nurse-driven targeted HIV screening in 8 emergency departments: study protocol for the DICI-VIH cluster-randomized two-period crossover trial. <i>BMC Infectious Diseases</i> , 2015, 16, 51.	2.9	4
135	Risk of HIV Transmission Under Combined Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, e41-e42.	2.1	2
136	Interobserver variability of cervical cytology in HIV-infected women. <i>Cytopathology</i> , 2015, 26, 362-367.	0.7	3
137	Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy. <i>HIV Medicine</i> , 2015, 16, 553-562.	2.2	49
138	Trends in survival after cancer diagnosis among HIV-infected individuals between 1992 and 2009. Results from the FHDH-ANRS CO4 cohort. <i>International Journal of Cancer</i> , 2015, 137, 2443-2453.	5.1	39
139	Later cART Initiation in Migrant Men from Sub-Saharan Africa without Advanced HIV Disease in France. <i>PLoS ONE</i> , 2015, 10, e0118492.	2.5	9
140	Is Impact of Statin Therapy on All-Cause Mortality Different in HIV-Infected Individuals Compared to General Population? Results from the FHDH-ANRS CO4 Cohort. <i>PLoS ONE</i> , 2015, 10, e0133358.	2.5	15
141	Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice. <i>PLoS ONE</i> , 2015, 10, e0144746.	2.5	2
142	A Multifaceted Intervention Designed to Improve Medical Management of Moderate to Advanced Chronic Kidney Disease in HIV-Infected Patients: A Cluster Randomized Trial. <i>Clinical Infectious Diseases</i> , 2015, 61, 375-384.	5.8	2
143	Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. <i>Neurology</i> , 2015, 84, 632-633.	1.1	62
144	Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?. <i>Aids</i> , 2015, 29, 2323-2333.	2.2	21

#	ARTICLE	IF	CITATIONS
145	Tackling latency as a barrier to an HIV cure: what next?. Lancet HIV, the, 2015, 2, e504-e505.	4.7	1
146	Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the ANRS (ANRS Nationale de Recherche sur le SIDA) (ANRS) 2010 survey. HIV Medicine, 2015, 16, 230-239.	2.2	71
147	Incidence of Herpes Zoster in HIV-Infected Adults in the Combined Antiretroviral Therapy Era: Results From the FHDH-ANRS CO4 Cohort. Clinical Infectious Diseases, 2015, 60, 1269-1277.	5.8	42
148	Boosted Lopinavir Versus Boosted Atazanavir-Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. Clinical Infectious Diseases, 2015, 60, 1262-1268.	5.8	6
149	Significant Reduction in HIV Virologic Failure During a 15-Year Period in a Setting With Free Healthcare Access. Clinical Infectious Diseases, 2015, 60, 463-472.	5.8	27
150	Myocardial Infarction in HIV-Infected Persons: Time to Focus on the Silent Elephant in the Room?. Clinical Infectious Diseases, 2015, 60, 1424-5.	5.8	1
151	Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial. Lancet HIV, the, 2015, 2, e82-e91.	4.7	34
152	Relevance of EORTC Criteria for the Diagnosis of Invasive Aspergillosis in HIV-Infected Patients, and Survival Trends Over a 20-Year Period in France. Clinical Infectious Diseases, 2015, 61, 1273-1280.	5.8	24
153	Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. Lancet HIV, the, 2015, 2, e335-e343.	4.7	52
154	High prevalence of Anal Human Papillomavirus-associated cancer precursors in a contemporary cohort of asymptomatic HIV-infected women. Clinical Infectious Diseases, 2015, 60, 1559-68.	5.8	32
155	GBD 2013 and HIV incidence in high income countries. Lancet, The, 2015, 385, 1177.	13.7	6
156	Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. Aids, 2015, 29, 221-229.	2.2	208
157	Obesity in HIV-infected patients in France: Prevalence and surgical treatment options. Journal of Visceral Surgery, 2015, 152, 33-37.	0.8	14
158	Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial). Journal of Antimicrobial Chemotherapy, 2015, 70, 3339-3344.	3.0	6
159	Impact of migration origin on individual protection strategies against sexual transmission of HIV in Paris metropolitan area, SIRS cohort study, France. BMC Public Health, 2015, 15, 807.	2.9	2
160	High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort. Clinical Infectious Diseases, 2015, 61, 1469-1475.	5.8	47
161	Burden of HIV and hepatitis C infection: the changing epidemiology of hepatitis C in HIV-infected patients in France. Liver International, 2015, 35, 65-70.	3.9	26
162	Which adults in the Paris metropolitan area have never been tested for HIV? A 2010 multilevel, cross-sectional, population-based study. BMC Infectious Diseases, 2015, 15, 278.	2.9	5

#	ARTICLE	IF	CITATIONS
163	Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 566-572.	3.0	8
164	Cancer-Related Causes of Death among HIV-Infected Patients in France in 2010: Evolution since 2000. <i>PLoS ONE</i> , 2015, 10, e0129550.	2.5	75
165	New indicators for delay in initiation of antiretroviral treatment: estimates for Cameroon. <i>Bulletin of the World Health Organization</i> , 2015, 93, 521-528.	3.3	9
166	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. <i>Eurosurveillance</i> , 2015, 20, .	7.0	70
167	Blunted Response to Combination Antiretroviral Therapy in HIV Elite Controllers: An International HIV Controller Collaboration. <i>PLoS ONE</i> , 2014, 9, e85516.	2.5	34
168	Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis. <i>Journal of the International AIDS Society</i> , 2014, 17, 19070.	3.0	6
169	CD4+ cell count recovery in naïve patients initiating cART, who achieved and maintained plasma HIV-RNA suppression. <i>Journal of the International AIDS Society</i> , 2014, 17, 19481.	3.0	12
170	Immunodeficiency at the Start of Combination Antiretroviral Therapy in Low-, Middle-, and High-Income Countries. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, e8-e16.	2.1	142
171	Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3356-3359.	3.0	2
172	Heterosexual Risk of HIV Transmission per Sexual Act Under Combined Antiretroviral Therapy: Systematic Review and Bayesian Modeling. <i>Clinical Infectious Diseases</i> , 2014, 59, 115-122.	5.8	30
173	Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies. <i>PLoS Medicine</i> , 2014, 11, e1001718.	8.4	100
174	Characteristics of B-Cell Lymphomas in HIV/HCV-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, e86-e87.	2.1	1
175	Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). <i>International Journal of Epidemiology</i> , 2014, 43, 691-702.	1.9	64
176	Vitamin D supplementation is associated with reduced immune activation levels in HIV-1-infected patients on suppressive antiretroviral therapy. <i>Aids</i> , 2014, 28, 2677-2682.	2.2	30
177	T-cell activation positively correlates with cell-associated HIV-DNA level in viremic patients with primary or chronic HIV-1 infection. <i>Aids</i> , 2014, 28, 1683-1687.	2.2	18
178	Causes of death among HIV-infected patients in France in 2010 (national survey). <i>Aids</i> , 2014, 28, 1181-1191.	2.2	223
179	Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009. <i>Aids</i> , 2014, 28, 2109-2118.	2.2	99
180	Demographics of HIV and aging. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 294-301.	3.8	77

#	ARTICLE	IF	CITATIONS
181	The undiagnosed HIV epidemic in France and its implications for HIV screening strategies. <i>Aids</i> , 2014, 28, 1797-1804.	2.2	72
182	Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4). <i>International Journal of Epidemiology</i> , 2014, 43, 1425-1436.	1.9	70
183	Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1648-1652.	3.0	29
184	Factors associated with short-term changes in HIV viral load and CD4+ cell count in antiretroviral-naïve individuals. <i>Aids</i> , 2014, 28, 1351-1356.	2.2	32
185	Is impaired kidney function an independent predictor of the risk of myocardial infarction in HIV-infected individuals?. <i>Aids</i> , 2014, 28, 1987-1989.	2.2	0
186	HIV-1 DNA Levels in Peripheral Blood Mononuclear Cells and Cannabis Use are Associated With Intermittent HIV Shedding in Semen of Men Who Have Sex With Men on Successful Antiretroviral Regimens. <i>Clinical Infectious Diseases</i> , 2014, 58, 1763-1770.	5.8	44
187	Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study. <i>Lancet HIV</i> , 2014, 1, e119-e126.	4.7	32
188	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. <i>Clinical Infectious Diseases</i> , 2014, 58, 1312-1321.	5.8	140
189	Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study. <i>BMC Infectious Diseases</i> , 2014, 14, 122.	2.9	51
190	Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. <i>Neurology</i> , 2014, 83, 134-141.	1.1	112
191	Critical Importance of Long-Term Adherence to Care in HIV Infected Patients in the cART Era: New Insights from <i>Pneumocystis jirovecii</i> Pneumonia Cases over 2004-2011 in the FHDH-ANRS CO4 Cohort. <i>PLoS ONE</i> , 2014, 9, e94183.	2.5	6
192	Metabolic Syndrome in a French Cohort of Patients With Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 1078-1085.	2.2	37
193	Risk of cancers in HIV infection. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2013, 31, 275-276.	0.5	1
194	HIV and Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2013, 61, 511-523.	2.8	234
195	Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy. <i>Aids</i> , 2013, 27, 635-643.	2.2	23
196	Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study. <i>PLoS Pathogens</i> , 2013, 9, e1003211.	4.7	879
197	Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). <i>PLoS Medicine</i> , 2013, 10, e1001510.	8.4	256
198	Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. <i>Journal of Infectious Diseases</i> , 2013, 207, 759-767.	4.0	7

#	ARTICLE	IF	CITATIONS
199	Risk of AIDS-Defining Cancers Among HIV-1-Infected Patients in France Between 1992 and 2009: Results From the FHDH-ANRS CO4 Cohort. <i>Clinical Infectious Diseases</i> , 2013, 57, 1638-1647.	5.8	92
200	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count $\geq 200$ Cells/ $\mu$ L in the Post-Combination Antiretroviral Therapy Era. <i>Clinical Infectious Diseases</i> , 2013, 57, 1038-1047.	5.8	92
201	$\beta$ -Blocker Use for Patients With or at Risk for Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 438.	7.4	4
202	Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts. <i>Clinical Infectious Diseases</i> , 2013, 56, 888-897.	5.8	88
203	Factors associated with late antiretroviral therapy initiation in Cameroon: a representative multilevel analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1388-1399.	3.0	28
204	National sentinel surveillance of transmitted drug resistance in antiretroviral-naïve chronically HIV-infected patients in France over a decade: 2001-2011. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2626-2631.	3.0	41
205	Prevalence of HIV-1 drug resistance in treated patients with viral load $> 50$ copies/mL in 2009: a French nationwide study. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1400-1405.	3.0	29
206	Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia. <i>Aids</i> , 2013, 27, 2425-2430.	2.2	41
207	Characteristics of B-Cell Lymphomas in HIV/HCV-Coinfected Patients During the Combined Antiretroviral Therapy Era. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 249-253.	2.1	12
208	Lack of regression of anal squamous intraepithelial lesions despite immune restoration under cART. <i>Aids</i> , 2013, 27, 401-406.	2.2	21
209	MHC-driven HIV-1 control on the long run is not systematically determined at early times post-HIV-1 infection. <i>Aids</i> , 2013, 27, 1707-1716.	2.2	13
210	Impact of Late Presentation on the Risk of Death Among HIV-Infected People in France (2003-2009). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 197-203.	2.1	54
211	Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. <i>Aids</i> , 2013, 27, 803-813.	2.2	70
212	Effect of Early Syphilis Infection on Plasma Viral Load and CD4 Cell Count in Human Immunodeficiency Virus-Infected Men. <i>Archives of Internal Medicine</i> , 2012, 172, 1237.	3.8	85
213	HIV Replication and Immune Status Are Independent Predictors of the Risk of Myocardial Infarction in HIV-Infected Individuals. <i>Clinical Infectious Diseases</i> , 2012, 55, 600-607.	5.8	141
214	Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. <i>International Journal of Epidemiology</i> , 2012, 41, 1807-1820.	1.9	34
215	Adverse Outcome Analyses of Observational Data: Assessing Cardiovascular Risk in HIV Disease. <i>Clinical Infectious Diseases</i> , 2012, 54, 408-413.	5.8	16
216	Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries. <i>Clinical Infectious Diseases</i> , 2012, 54, 1364-1372.	5.8	58

#	ARTICLE	IF	CITATIONS
217	Single-Nucleotide Polymorphism-Defined Class I and Class III Major Histocompatibility Complex Genetic Subregions Contribute to Natural Long-term Nonprogression in HIV Infection. <i>Journal of Infectious Diseases</i> , 2012, 205, 718-724.	4.0	28
218	Effect of Alendronate on HIV-Associated Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled, 96-Week Trial (ANRS 120). <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 972-980.	1.1	36
219	Incidence of HIV-Related Anal Cancer Remains Increased Despite Long-Term Combined Antiretroviral Treatment: Results From the French Hospital Database on HIV. <i>Journal of Clinical Oncology</i> , 2012, 30, 4360-4366.	1.6	145
220	Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor. <i>Aids</i> , 2012, 26, 1801-1805.	2.2	7
221	Undiagnosed HIV prevalence in France. <i>Aids</i> , 2012, 26, 2419.	2.2	1
222	Determinants of low-density lipoprotein particle diameter during antiretroviral therapy including protease inhibitors in HIV-1-infected patients. <i>Antiviral Therapy</i> , 2012, 17, 855-860.	1.0	6
223	Is The Age-Period-Cohort Model Well Suited to an Epidemic Context? The Case of the French BSE Epidemic. <i>Statistical Communications in Infectious Diseases</i> , 2012, 4, .	0.2	0
224	Boosted protease inhibitor monotherapy as a maintenance strategy. <i>Aids</i> , 2012, 26, 2345-2350.	2.2	23
225	Performance of Quantiferon-® for the diagnosis TB. <i>Médecine Et Maladies Infectieuses</i> , 2012, 42, 579-584.	5.0	2
226	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 119-127.	9.1	41
227	NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients. <i>European Journal of Immunology</i> , 2012, 42, 3038-3048.	2.9	30
228	Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2487-2493.	3.0	4
229	Breast cancer among HIV infected individuals from the ONCOVIH study, in France: Therapeutic implications. <i>European Journal of Cancer</i> , 2012, 48, 3335-3341.	2.8	22
230	Prevalence of Low Bone Mineral Density in Men and Women Infected With Human Immunodeficiency Virus 1 and a Proposal for Screening Strategy. <i>Journal of Clinical Densitometry</i> , 2012, 15, 422-433.	1.2	19
231	Twelve Months of Routine HIV Screening in 6 Emergency Departments in the Paris Area: Results from the ANRS URDEP Study. <i>PLoS ONE</i> , 2012, 7, e46437.	2.5	29
232	Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 104-112.	1.7	23
233	The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. <i>Aids</i> , 2012, 26, 1691-1705.	2.2	31
234	Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 294-299.	2.1	13

#	ARTICLE	IF	CITATIONS
235	HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. <i>Blood</i> , 2011, 117, 5142-5151.	1.4	140
236	Risk of triple-class virological failure in children with HIV: a retrospective cohort study. <i>Lancet</i> , The, 2011, 377, 1580-1587.	13.7	101
237	Épidémiologie du cancer de l'anus. <i>Cancer Digest</i> , 2011, , .	0.0	1
238	Improved Survival of HIV-1-Infected Patients with Progressive Multifocal Leukoencephalopathy Receiving Early 5-Drug Combination Antiretroviral Therapy. <i>PLoS ONE</i> , 2011, 6, e20967.	2.5	58
239	New method for estimating HIV incidence and time from infection to diagnosis using HIV surveillance data. <i>Aids</i> , 2011, 25, 1905-1913.	2.2	44
240	Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial. <i>Aids</i> , 2011, 25, 115-118.	2.2	28
241	Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. <i>Aids</i> , 2011, 25, 1813-1822.	2.2	140
242	Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. <i>Aids</i> , 2011, 25, 27-36.	2.2	40
243	HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. <i>Blood</i> , 2011, 118, 44-49.	1.4	62
244	When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries. <i>Annals of Internal Medicine</i> , 2011, 154, 509.	3.9	205
245	Late presentation of HIV infection: a consensus definition. <i>HIV Medicine</i> , 2011, 12, 61-64.	2.2	378
246	The spectrum of malignancies in HIV-infected patients in 2006 in France: The ONCOVIH study. <i>International Journal of Cancer</i> , 2011, 129, 467-475.	5.1	77
247	Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 182-190.	1.7	27
248	Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1869-1877.	3.0	7
249	Survival after neuroAIDS. <i>Neurology</i> , 2011, 76, 644-651.	1.1	37
250	High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors. <i>Aids</i> , 2011, 25, 1128-1131.	2.2	35
251	Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis. <i>European Heart Journal</i> , 2011, 32, 41-50.	2.2	99
252	A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2011, 203, 473-478.	4.0	105

#	ARTICLE	IF	CITATIONS
253	HIV in hiding: methods and data requirements for the estimation of the number of people living with undiagnosed HIV. <i>Aids</i> , 2011, 25, 1017-1023.	2.2	37
254	The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. <i>Aids</i> , 2010, 24, 123-137.	2.2	360
255	Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. <i>Aids</i> , 2010, 24, 614-617.	2.2	41
256	Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets. <i>Aids</i> , 2010, 24, 365-371.	2.2	5
257	Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. <i>Archives of Internal Medicine</i> , 2010, 170, 410-419.	3.8	42
258	A Meta-Analysis of Six Placebo-Controlled Trials of Thiazolidinedione Therapy for HIV Lipodystrophy. <i>HIV Clinical Trials</i> , 2010, 11, 39-50.	2.0	29
259	Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. <i>Aids</i> , 2010, 24, 77-83.	2.2	74
260	HIV-associated tuberculosis and immigration in a high-income country: incidence trends and risk factors in recent years. <i>Aids</i> , 2010, 24, 763-771.	2.2	24
261	When to Start Treatment? A Systematic Approach to the Comparison of Dynamic Regimes Using Observational Data. <i>International Journal of Biostatistics</i> , 2010, 6, Article 18.	0.7	160
262	Abacavir and Cardiovascular Risk: Reviewing the Evidence. <i>Current HIV/AIDS Reports</i> , 2010, 7, 127-133.	3.1	36
263	Skin cancers associated with HIV infection and solid-organ transplantation among elderly adults. <i>International Journal of Cancer</i> , 2010, 126, 1724-1731.	5.1	102
264	A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir. <i>Journal of Medical Virology</i> , 2010, 82, 1819-1828.	5.0	46
265	Preferential Amplification of CD8 Effector-T Cells after Transcutaneous Application of an Inactivated Influenza Vaccine: A Randomized Phase I Trial. <i>PLoS ONE</i> , 2010, 5, e10818.	2.5	92
266	Relationship between Regulatory T Cells and Immune Activation in Human Immunodeficiency Virus-Infected Patients Interrupting Antiretroviral Therapy. <i>PLoS ONE</i> , 2010, 5, e11659.	2.5	45
267	Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness. <i>PLoS ONE</i> , 2010, 5, e13132.	2.5	93
268	Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human Immunodeficiency Virus-Infected Patients; A Case-Control Study Nested Within the French Hospital Database on HIV ANRS Cohort CO4. <i>Archives of Internal Medicine</i> , 2010, 170, 1228.	3.8	266
269	Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naïve chronically HIV-infected patients from 2001 to 2006/2007 in France. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2620-2627.	3.0	62
270	Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy?. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 138-144.	3.0	5



#	ARTICLE	IF	CITATIONS
271	Causes of Death in HIV-Infected Patients Treated with Antiretroviral Therapy, 1996-2006: Collaborative Analysis of 13 HIV Cohort Studies. <i>Clinical Infectious Diseases</i> , 2010, 50, 1387-1396.	5.8	525
272	Causes of death in HIV-infected women: persistent role of AIDS. The 'Mortalite 2000 & 2005' Surveys (ANRS EN19). <i>International Journal of Epidemiology</i> , 2010, 39, 135-146.	1.9	25
273	IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy--results from the ANRS CO4 cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2215-2223.	3.0	7
274	Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 556-561.	3.0	32
275	Resistance-Associated Mutations to Etravirine (TMC-125) in Antiretroviral-Naïve Patients Infected with Non-B HIV-1 Subtypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 728-733.	3.2	44
276	Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosine. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 752-760.	3.0	5
277	Kaposi Sarcoma Incidence and Survival Among HIV-Infected Homosexual Men After HIV Seroconversion. <i>Journal of the National Cancer Institute</i> , 2010, 102, 784-792.	6.3	111
278	Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. <i>Aids</i> , 2010, 24, 1228-1230.	2.2	256
279	Enoxaparin Anticoagulation Monitoring in the Catheterization Laboratory Using a New Bedside Test. <i>Journal of the American College of Cardiology</i> , 2010, 55, 617-625.	2.8	22
280	Early initiation of treatment for HIV infection. <i>Lancet</i> , The, 2010, 375, 639.	13.7	4
281	Better health-related quality of life after switching from a virologically effective regimen to a regimen containing efavirenz or nevirapine. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2010, 22, 54-61.	1.2	13
282	The Cost of Managing HIV Infection in Highly Treatment-Experienced, HIV-Infected Adults in France. <i>Pharmacoeconomics</i> , 2010, 28, 59-68.	3.3	10
283	Modelling the Budget Impact of Darunavir in the Treatment of Highly Treatment-Experienced, HIV-Infected Adults in France. <i>Pharmacoeconomics</i> , 2010, 28, 183-197.	3.3	7
284	Distinct differentiation profiles of HIV-Gag and Nef-specific central memory CD8+ T cells associated with HLA-B57/5801 and virus control. <i>Aids</i> , 2010, 24, 2323-2329.	2.2	15
285	Low Prevalence of HIV Type 1 Drug Resistance Mutations in Untreated, Recently Infected Patients from Burkina Faso, Côte d'Ivoire, Senegal, Thailand, and Vietnam: The ANRS 12134 Study. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 1193-1196.	1.1	40
286	HEPATITIS B VACCINE AND THE RISK OF CNS INFLAMMATORY DEMYELINATION IN CHILDHOOD. <i>Neurology</i> , 2009, 73, 1426-1427.	1.1	3
287	Interleukine-2 Therapy Does Not Increase the Risk of Hodgkin or Non-Hodgkin Lymphoma in HIV-Infected Patients: Results From FHDH ANRS CO4. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 206-214.	2.1	9
288	Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts < 350 cells/µl. <i>Aids</i> , 2009, 23, 1997-2004.	2.2	28

#	ARTICLE	IF	CITATIONS
289	Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase) Tj ETQq1 1 0.784314 rgBT /Overlock 11 nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. <i>Aids</i> , 2009, 23, 1605-1608.	2.2	10
290	A Step Ahead on the HIV Collaboratory. <i>Science</i> , 2009, 324, 1264-1265.	12.6	4
291	Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. <i>International Journal of Epidemiology</i> , 2009, 38, 1624-1633.	1.9	173
292	Observation plans in longitudinal studies with time-varying treatments. <i>Statistical Methods in Medical Research</i> , 2009, 18, 27-52.	1.5	73
293	Changes in Cancer Mortality among HIVâ€infecteD Patients: The MortalitÃ© 2005 Survey. <i>Clinical Infectious Diseases</i> , 2009, 48, 633-639.	5.8	147
294	Anticardiolipin Antibodies in HIV Infection Are Independently Associated with Antibodies to the Membrane Proximal External Region of gp41 and with Cellâ€Associated HIV DNA and Immune Activation. <i>Clinical Infectious Diseases</i> , 2009, 48, 123-132.	5.8	59
295	How does loss to followâ€up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, MortalitÃ© 2000 survey and death certificates<sup>*</sup>. <i>HIV Medicine</i> , 2009, 10, 236-245.	2.2	24
296	Liverâ€related deaths in HIVâ€infecteD patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 Study in collaboration with the MortalitÃ© 2005 survey, ANRS) Tj ETQq0 0 0 rgBT /Overlock 11 Tf 50 45	2.2	10
297	Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, 10-20.	4.4	63
298	Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national MortalitÃ© 2005 study. <i>Journal of Hepatology</i> , 2009, 50, 736-745.	3.7	102
299	Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. <i>Retrovirology</i> , 2009, 6, 49.	2.0	114
300	Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. <i>Lancet Oncology</i> , The, 2009, 10, 1152-1159.	10.7	486
301	Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. <i>Lancet</i> , The, 2009, 373, 1352-1363.	13.7	676
302	Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. <i>Aids</i> , 2009, 23, 817-824.	2.2	212
303	Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. <i>Aids</i> , 2009, 23, 1163-1169.	2.2	165
304	Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. <i>Aids</i> , 2009, 23, 2199-2208.	2.2	40
305	Effect of Baseline CD4 Cell Counts on the Clinical Significance of Short-Term Immunologic Response to Antiretroviral Therapy in Individuals With Virologic Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 357-363.	2.1	26
306	Trends in Post-Infection CD4 Cell Counts and Plasma HIV-1 RNA Levels in HIV-1â€infecteD Patients in France Between 1997 and 2005. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 422-426.	2.1	13

#	ARTICLE	IF	CITATIONS
307	Incidence and Risk Factors of HIV-Related Non-Hodgkin's Lymphoma in the era of Combination Antiretroviral Therapy: A European Multicohort Study. <i>Antiviral Therapy</i> , 2009, 14, 1065-1074.	1.0	92
308	Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. <i>Aids</i> , 2009, 23, 2029-2037.	2.2	64
309	Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. <i>Aids</i> , 2009, 23, 1743-1753.	2.2	200
310	Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. <i>Aids</i> , 2009, 23, 717-724.	2.2	73
311	R�le de lâenveloppe GP 41 dans la pr�paration d�un candidat vaccin contre le VIH. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2009, 193, 127-138.	0.0	0
312	CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4+ T-cell counts >200 cells/mm <sup>3</sup> . <i>Antiviral Therapy</i> , 2009, 14, 451-7.	1.0	9
313	CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4+ T-cell counts >200 cells/mm <sup>3</sup> . <i>Antiviral Therapy</i> , 2009, 14, 451-457.	1.0	25
314	Influence of control selection in nested case-control studies: the example of exposure to antiretroviral treatment (ART) and the risk of myocardial infarction (MI) in the French Hospital Database on HIV (FHDH-ANRS CO4). <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 468-474.	1.9	2
315	National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation. <i>Journal of Medical Virology</i> , 2008, 80, 762-765.	5.0	6
316	Nevirapine-associated toxicity in Niger. <i>HIV Medicine</i> , 2008, 9, 62-63.	2.2	5
317	Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response. <i>HIV Medicine</i> , 2008, 9, 27-40.	2.2	6
318	Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. <i>HIV Medicine</i> , 2008, 9, 246-256.	2.2	58
319	Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial. <i>HIV Medicine</i> , 2008, 9, 625-635.	2.2	21
320	Surgical management of cervical intraepithelial neoplasia in HIV-infected women. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2008, 141, 153-157.	1.1	23
321	Maintaining Antiretroviral Therapy Reduces the Risk of AIDS-Defining Events in Patients with Uncontrolled Viral Replication and Profound Immunodeficiency. <i>Clinical Infectious Diseases</i> , 2008, 46, 296-304.	5.8	63
322	Characteristics of the env Genes of HIV Type 1 Quasispecies in Long-Term Nonprogressors With Broadly Neutralizing Antibodies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 274-284.	2.1	20
323	Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. <i>Aids</i> , 2008, 22, 1203-1211.	2.2	240
324	Imported Malaria in HIV-Infected Patients Enrolled in the ANRS CO4 FHDH Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 49, 55-60.	2.1	25

#	ARTICLE	IF	CITATIONS
325	AIDS-Related Malignancies: State of the Art and Therapeutic Challenges. <i>Journal of Clinical Oncology</i> , 2008, 26, 4834-4842.	1.6	110
326	Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 797-808.	3.0	23
327	Transcutaneous Anti-Influenza Vaccination Promotes Both CD4 and CD8 T Cell Immune Responses in Humans. <i>Journal of Immunology</i> , 2008, 180, 1482-1489.	0.8	101
328	HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 451-455.	3.0	6
329	Initiatives for Developing and Comparing Genotype Interpretation Systems: External Validation of Existing Systems for Didanosine against Virological Response. <i>Journal of Infectious Diseases</i> , 2008, 198, 470-480.	4.0	11
330	Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 1362-1368.	3.0	14
331	Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. <i>Aids</i> , 2008, 22, 1125-1129.	2.2	139
332	One or two enzyme-linked immunosorbent assay tests on the first serum sample for initial diagnosis of HIV-1 infection?. <i>Aids</i> , 2008, 22, 2042-2044.	2.2	3
333	Increased cardiovascular risk in HIV infection: drugs, virus and immunity. <i>Aids</i> , 2008, 22, 1625-1627.	2.2	14
334	Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). <i>Aids</i> , 2008, 22, 1313-1322.	2.2	77
335	Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?. <i>Aids</i> , 2008, 22, 2481-2492.	2.2	18
336	Changes in Causes of Death Among Adults Infected by HIV Between 2000 and 2005: The "Mortality" 2000 and 2005 Surveys (ANRS EN19 and Mortavic). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 590-598.	2.1	313
337	Dual Nucleoside Reverse Transcriptase Inhibitor Therapy in the Combination Antiretroviral Therapy Era and Predictors of Discontinuation or Switch to Combination Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 206-211.	2.1	3
338	Clinical Progression Rates by CD4 Cell Category Before and After the Initiation of Combination Antiretroviral Therapy (cART). <i>Open AIDS Journal</i> , 2008, 2, 3-9.	0.5	13
339	Visual Versus Instrumental Perception of Haze--A Review. <i>Technical Quarterly</i> , 2008, , .	0.2	0
340	Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). <i>Antiviral Therapy</i> , 2008, 13, 67-76.	1.0	31
341	Effect of Pioglitazone on HIV-1-Related Lipodystrophy: A Randomized Double-Blind Placebo-Controlled Trial (ANRS 113). <i>Antiviral Therapy</i> , 2008, 13, 67-76.	1.0	76
342	Do Tests Devised to Detect Recent HIV-1 Infection Provide Reliable Estimates of Incidence in Africa?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, 115-122.	2.1	53

#	ARTICLE	IF	CITATIONS
343	Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. <i>Journal of Experimental Medicine</i> , 2007, 204, 2473-2485.	8.5	655
344	Serious psychiatric outcome of subjects prenatally exposed to diethylstilboestrol in the E3N cohort study. <i>Psychological Medicine</i> , 2007, 37, 1315-1322.	4.5	15
345	Comparative Biological and Clinical Outcomes after a Switch from a Virologically Unsuccessful First Protease Inhibitor-Containing Antiretroviral Combination to a 3-Drug Regimen Containing Efavirenz, Nevirapine, or Abacavir. <i>Clinical Infectious Diseases</i> , 2007, 44, 120-127.	5.8	4
346	Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. <i>Aids</i> , 2007, 21, 1185-1197.	2.2	264
347	HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART. <i>Aids</i> , 2007, 21, 2243-2245.	2.2	27
348	Observation versus intervention in the evaluation of drugs: the story of hormone replacement therapy. <i>Comptes Rendus - Biologies</i> , 2007, 330, 347-355.	0.2	2
349	Estimating incidence of the French BSE infection using a joint analysis of both asymptomatic and clinical BSE surveillance data. <i>Mathematical Biosciences</i> , 2007, 209, 90-107.	1.9	8
350	Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. <i>Journal of Infection</i> , 2007, 54, 367-374.	3.3	50
351	BSE Risk Assessment as a Basis for Updating French Screening Policy. <i>Risk Analysis</i> , 2007, 27, 1131-1140.	2.7	3
352	Complementary Approach of Data Analysis and Modeling to Estimate the Pattern of the BSE Epidemic: The Example of France. <i>Risk Analysis</i> , 2007, 27, 1141-1150.	2.7	8
353	HIV-associated <i>Isospora belli</i> infection: incidence and risk factors in the French Hospital Database on HIV. <i>HIV Medicine</i> , 2007, 8, 124-130.	2.2	23
354	Wild type and H43Y variant of human TRIM5 $\alpha$ show similar anti-human immunodeficiency virus type 1 activity both in vivo and in vitro. <i>Immunogenetics</i> , 2007, 59, 511-515.	2.4	25
355	Prevalence of HIV-1 Drug Resistance in Treated Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 12-18.	2.1	48
356	Frequency, determinants and consequences of delayed access to care for HIV infection in France. <i>Antiviral Therapy</i> , 2007, 12, 89-96.	1.0	89
357	First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes. <i>Antiviral Therapy</i> , 2007, 12, 317-24.	1.0	5
358	First-line Highly Active Antiretroviral Regimens in 2001-2002 in the French Hospital Database on HIV: Combination Prescribed and Biological Outcomes. <i>Antiviral Therapy</i> , 2007, 12, 317-324.	1.0	12
359	A 6-Month Interruption of Antiretroviral Therapy Improves Adipose Tissue Function in HIV-Infected Patients: The ANRS EP29 Lipostop Study. <i>Antiviral Therapy</i> , 2007, 12, 1273-1284.	1.0	35
360	Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network. <i>Antiviral Therapy</i> , 2007, 12, 1305-1310.	1.0	30

#	ARTICLE	IF	CITATIONS
361	HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. <i>Lancet, The</i> , 2006, 368, 451-458.	13.7	209
362	Effects of type of smoking (pipe, cigars or cigarettes) on biological indices of tobacco exposure and toxicity. <i>Lung Cancer</i> , 2006, 54, 11-18.	2.0	44
363	How was the French BSE epidemic underestimated?. <i>Comptes Rendus - Biologies</i> , 2006, 329, 106-116.	0.2	9
364	Predictors identified for losses to follow-up among HIV-seropositive patients. <i>Journal of Clinical Epidemiology</i> , 2006, 59, 829-829.	5.0	85
365	Number of deaths among HIV-infected adults in France in 2000, three-source capture-recapture estimation. <i>Epidemiology and Infection</i> , 2006, 134, 1345-1352.	2.1	27
366	Specific adaptive humoral response against a gp41 motif inhibits CD4 T-cell sensitivity to NK lysis during HIV-1 infection. <i>Aids</i> , 2006, 20, 1795-1804.	2.2	30
367	Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. <i>Aids</i> , 2006, 20, 1923-1930.	2.2	60
368	Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy. <i>Aids</i> , 2006, 20, 1627-1635.	2.2	51
369	Yearly number of patients diagnosed with primary HIV-1 infection in France estimated by a capture-recapture approach. <i>Aids</i> , 2006, 20, 2392-2395.	2.2	11
370	On the comparison of artificial network and interpretation systems based on genotype resistance mutations in HIV-1-infected patients. <i>Aids</i> , 2006, 20, 2118-2120.	2.2	0
371	The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 41, 352-360.	2.1	90
372	Influence of gender and HIV transmission group on initial highly active antiretroviral therapy prescription and treatment response. <i>HIV Medicine</i> , 2006, 7, 520-529.	2.2	29
373	Comparison of Dynamic Treatment Regimes via Inverse Probability Weighting. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006, 98, 237-242.	2.5	210
374	Including pre-AIDS mortality in back-calculation model to estimate HIV prevalence in France, 2000. <i>European Journal of Epidemiology</i> , 2006, 21, 389-396.	5.7	8
375	Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. <i>Journal of Medical Virology</i> , 2006, 78, 153-160.	5.0	53
376	Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir. <i>Aids</i> , 2006, 20, 2099-2106.	2.2	11
377	HIV infection in older patients in the HAART era. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 4-7.	3.0	121
378	Rates of Disease Progression according to Initial Highly Active Antiretroviral Therapy Regimen: A Collaborative Analysis of 12 Prospective Cohort Studies. <i>Journal of Infectious Diseases</i> , 2006, 194, 612-622.	4.0	42

#	ARTICLE	IF	CITATIONS
379	Differential Impact of Combination Antiretroviral Therapy in Preventing Kaposi's Sarcoma With and Without Visceral Involvement. <i>Journal of Clinical Oncology</i> , 2006, 24, 3408-3414.	1.6	57
380	Phase II Trial of CHOP Plus Rituximab in Patients With HIV-Associated Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 4123-4128.	1.6	199
381	Lamivudine and Indinavir/Ritonavir Maintenance Therapy in Highly Pretreated HIV-Infected Patients (Vista Anrs 109). <i>Antiviral Therapy</i> , 2006, 11, 889-900.	1.0	4
382	Limited Impact of Immunosuppression and Haart on the Incidence of Cervical Squamous Intraepithelial Lesions in HIV-Positive Women. <i>Antiviral Therapy</i> , 2006, 11, 1091-1096.	1.0	27
383	High Rate of Recurrence of Cervical Intraepithelial Neoplasia After Surgery in HIV-Positive Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 412-418.	2.1	52
384	Response to Highly Active Antiretroviral Therapy at 6 Months and Long-Term Disease Progression in HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 284-292.	2.1	32
385	No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients. <i>Aids</i> , 2005, 19, 1643-1647.	2.2	45
386	French National Sentinel Survey of Antiretroviral Drug Resistance in Patients With HIV-1 Primary Infection and in Antiretroviral-Naive Chronically Infected Patients in 2001-2002. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 545-552.	2.1	110
387	Alterations of self-reactive antibody repertoires in HIV disease: An insight into the role of T cells in the selection of autoreactive B cells. <i>Immunology Letters</i> , 2005, 99, 198-208.	2.5	28
388	Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV-1-infected patients: A French nationwide study. <i>Journal of Medical Virology</i> , 2005, 76, 441-446.	5.0	10
389	Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS) Tj ETQq1 1 0.784314 23BT /Over	2.2	43
390	Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France. <i>Scandinavian Journal of Infectious Diseases</i> , 2005, 37, 482-487.	1.5	61
391	Combination of HIV-1 Specific CD4 Th1 Cell Responses and IgG2 Antibodies Is the Best Predictor for Persistence of Long-Term Nonprogression. <i>Journal of Infectious Diseases</i> , 2005, 191, 2053-2063.	4.0	121
392	Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management. <i>Journal of Infectious Diseases</i> , 2005, 192, 958-966.	4.0	385
393	Development and Validation of an Immunoassay for Identification of Recent Human Immunodeficiency Virus Type 1 Infections and Its Use on Dried Serum Spots. <i>Journal of Clinical Microbiology</i> , 2005, 43, 4441-4447.	3.9	88
394	Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. <i>Journal of Experimental Medicine</i> , 2005, 201, 1999-2010.	8.5	105
395	Evaluation of a peer support group therapy for HIV-infected adolescents. <i>Aids</i> , 2005, 19, 1501-1508.	2.2	112
396	Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. <i>Aids</i> , 2005, 19, 25-33.	2.2	56

#	ARTICLE	IF	CITATIONS
397	Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. <i>Journal of Hepatology</i> , 2005, 42, 799-805.	3.7	302
398	Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). <i>Vaccine</i> , 2005, 23, 4292-4301.	3.8	46
399	Impact of newly available drugs on clinical progression in patients with virological failure after exposure to three classes of antiretrovirals. <i>Antiviral Therapy</i> , 2005, 10, 563-73.	1.0	3
400	Impact of Newly Available Drugs on Clinical Progression in Patients with Virological Failure after Exposure to Three Classes of Antiretrovirals. <i>Antiviral Therapy</i> , 2005, 10, 563-573.	1.0	10
401	Comparison of the Dynamics of Resistance-Associated Mutations to Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors after Cessation of Antiretroviral Combination Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 644-647.	3.2	16
402	Nucleoside Analogue Use Before and During Highly Active Antiretroviral Therapy and Virus Load Rebound. <i>Journal of Infectious Diseases</i> , 2004, 190, 675-687.	4.0	6
403	Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. <i>International Journal of Epidemiology</i> , 2004, 34, 121-130.	1.9	321
404	Clinically Relevant Interpretation of Genotype and Relationship to Plasma Drug Concentrations for Resistance to Saquinavir-Ritonavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4687-4692.	3.2	48
405	Contraceptive Use in HIV-Positive Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 36, 714-720.	2.1	26
406	GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy*. <i>HIV Medicine</i> , 2004, 5, 352-359.	2.2	63
407	Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. <i>Cancer</i> , 2004, 101, 317-324.	4.1	216
408	Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients. <i>Journal of Medical Virology</i> , 2004, 74, 16-20.	5.0	22
409	Evaluating therapeutic vaccines in patients infected with HIV. <i>Expert Review of Vaccines</i> , 2004, 3, S169-S177.	4.4	12
410	Comparing the public health burden of chronic hepatitis C and HIV infection in France. <i>Journal of Hepatology</i> , 2004, 40, 319-326.	3.7	59
411	Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures. <i>Aids</i> , 2004, 18, 217-226.	2.2	78
412	Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. <i>Aids</i> , 2004, 18, 2029-2038.	2.2	168
413	The unrecognised French BSE epidemic. <i>Veterinary Research</i> , 2004, 35, 349-362.	3.0	43
414	Genotypic Determinants of the Virological Response to Tenofovir Disoproxil Fumarate in Nucleoside Reverse Transcriptase Inhibitor-Experienced Patients. <i>Antiviral Therapy</i> , 2004, 9, 315-323.	1.0	35



#	ARTICLE	IF	CITATIONS
415	Impact of Insertions in the HIV-1 P6 P <sub>1</sub> Region on the Virological Response to Amprenavir. <i>Antiviral Therapy</i> , 2004, 9, 221-227.	1.0	18
416	Clinically Validated Genotype Analysis: Guiding Principles and Statistical Concerns. <i>Antiviral Therapy</i> , 2004, 9, 465-478.	1.0	58
417	Quantitation of cytomegalovirus (CMV) DNA by real-time PCR for occurrence of CMV disease in HIV-infected patients receiving highly active antiretroviral therapy. <i>Journal of Medical Virology</i> , 2003, 69, 401-407.	5.0	16
418	Markov modelling of changes in HIV-specific cytotoxic T-lymphocyte responses with time in untreated HIV-1 infected patients. <i>Statistics in Medicine</i> , 2003, 22, 1675-1690.	1.6	13
419	Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. <i>Lancet</i> , The, 2003, 362, 679-686.	13.7	234
420	Clinical and Immunologic Outcome in Patients with Human Immunodeficiency Virus Infection, According to Virologic Efficacy in the Year after Virus Undetectability, during Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2003, 37, 1517-1526.	5.8	21
421	Incidence of Non-AIDS-Defining Cancers Before and During the Highly Active Antiretroviral Therapy Era in a Cohort of Human Immunodeficiency Virus-Infected Patients. <i>Journal of Clinical Oncology</i> , 2003, 21, 3447-3453.	1.6	345
422	Genotypic Inhibitory Quotient as Predictor of Virological Response to Ritonavir-Amprenavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 594-600.	3.2	96
423	Bivariate Longitudinal Model For The Analysis Of The Evolution Of Hiv Rna And Cd4 Cell Count In Hiv Infection Taking Into Account Left Censoring Of Hiv Rna Measures. <i>Journal of Biopharmaceutical Statistics</i> , 2003, 13, 271-282.	0.8	17
424	No influence of human herpesvirus 8 infection on the progression of HIV-1 infection in initially asymptomatic patients. <i>Aids</i> , 2003, 17, 1394-1396.	2.2	5
425	Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. <i>Aids</i> , 2003, 17, 2479-2486.	2.2	477
426	Modeling the Time Course of CD4 T-Lymphocyte Counts According to the Level of Virologic Rebound in HIV-1-Infected Patients on Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, 50-57.	2.1	19
427	Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. <i>Aids</i> , 2003, 17, 2635-2643.	2.2	100
428	Poly lactic acid implants (New-Fill) <sup>®</sup> to correct facial lipoatrophy in HIV-infected patients. <i>Aids</i> , 2003, 17, 2471-2477.	2.2	320
429	IL-2 therapy and thymic production of naive CD4 T cells in HIV-infected patients with severe CD4 lymphopenia. <i>Aids</i> , 2003, 17, 841-850.	2.2	25
430	Clinically relevant interpretation of genotype for resistance to abacavir. <i>Aids</i> , 2003, 17, 1795-1802.	2.2	60
431	Quantitative markers for cytomegalovirus disease in HIV-infected patients receiving highly active antiretroviral therapy. <i>Aids</i> , 2003, 17, 784-786.	2.2	1
432	Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). <i>Antiviral Therapy</i> , 2003, 8, 427-34.	1.0	13

#	ARTICLE	IF	CITATIONS
433	Increase of HIV-1 Pro-Viral Dna per Million Peripheral Blood Mononuclear Cells in Patients with Advanced HIV Disease (Cd4<math>\lt; 200</math> Cells/Mm<sup>3</sup>) Receiving Interleukin 2 Combined with Haart Versus Haart Alone (Anrs-082 Trial). <i>Antiviral Therapy</i> , 2003, 8, 233-237.	1.0	6
434	Predictors of the Virological Response to a Change in the Antiretroviral Treatment Regimen in HIV-1-Infected Patients Enrolled in a Randomized Trial Comparing Genotyping, Phenotyping and Standard of Care (Narval Trial, Anrs 088). <i>Antiviral Therapy</i> , 2003, 8, 427-434.	1.0	46
435	The Incubation Period of Kuru. <i>Epidemiology</i> , 2002, 13, 402-408.	2.7	36
436	Semen alterations in HIV-1 infected men. <i>Human Reproduction</i> , 2002, 17, 2112-2118.	0.9	118
437	Impact of Highly Active Antiretroviral Therapy on the Incidence of Visceral Leishmaniasis in a French Cohort of Patients Infected with Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2002, 186, 1366-1370.	4.0	74
438	Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection. <i>Aids</i> , 2002, 16, 2399-2407.	2.2	73
439	Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy. <i>Aids</i> , 2002, 16, 2027-2034.	2.2	67
440	Time to AIDS From 1992 to 1999 in HIV-1-Infected Subjects With Known Date of Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 30, 81-87.	2.1	27
441	Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. <i>Aids</i> , 2002, 16, 727-736.	2.2	202
442	Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. <i>Lancet</i> , The, 2002, 360, 119-129.	13.7	1,415
443	Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort. <i>British Journal of Haematology</i> , 2002, 116, 383-389.	2.5	9
444	Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: Results from a randomized control trial. <i>Hepatology</i> , 2002, 35, 238-239.	7.3	9
445	Decrease in HIV-1 seminal shedding in men receiving highly active antiretroviral therapy: an 18 month longitudinal study (ANRS EP012). <i>Aids</i> , 2002, 16, 486-488.	2.2	58
446	Time to AIDS From 1992 to 1999 in HIV-1-Infected Subjects With Known Date of Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 30, 81-87.	2.1	10
447	Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. <i>Antiviral Therapy</i> , 2002, 7, 211-8.	1.0	11
448	Impact of Stavudine Phenotype and Thymidine Analogues Mutations on Viral Response to Stavudine plus Lamivudine in Altis 2 Anrs Trial. <i>Antiviral Therapy</i> , 2002, 7, 211-218.	1.0	28
449	HIV Type 1-Specific IgG2 Antibodies: Markers of Helper T Cell Type 1 Response and Prognostic Marker of Long-Term Nonprogression. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1435-1446.	1.1	81
450	Incidence and Risk Factors for Toxoplasmic Encephalitis in Human Immunodeficiency Virus-Infected Patients before and during the Highly Active Antiretroviral Therapy Era. <i>Clinical Infectious Diseases</i> , 2001, 33, 1747-1755.	5.8	122

#	ARTICLE	IF	CITATIONS
451	Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. <i>Blood</i> , 2001, 98, 2339-2344.	1.4	370
452	Primary Prevention With Cotrimoxazole for HIV-1â€“Infected Adults: Results of the Pilot Study in Dakar, Senegal. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 26, 130-136.	2.1	22
453	<i>Pneumocystis carinii</i> Pneumonia Recurrence in HIV Patients on Highly Active Antiretroviral Therapy: Secondary Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 26, 151-158.	2.1	11
454	Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: a caseâ€“control study. <i>Aids</i> , 2001, 15, 2011-2016.	2.2	34
455	HIV Incidence Estimates Among Women of Childbearing Age in the Area Around Paris, France: No Evidence for Any Effect of Age or Time. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 27, 492-498.	2.1	0
456	Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective. <i>Vox Sanguinis</i> , 2001, 80, 199-204.	1.5	21
457	Prevalence of resistance mutations in antiretroviral-naïve chronically HIV-infected patients in 1998: a French nationwide study. <i>Aids</i> , 2001, 15, 1777-1782.	2.2	33
458	<i>Pneumocystis carinii</i> Pneumonia Recurrence in HIV Patients on Highly Active Antiretroviral Therapy: Secondary Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 26, 151-158.	2.1	7
459	The French haemophilia cohort: rationale and organization of a long-term national pharmacosurveillance system. <i>Haemophilia</i> , 2001, 7, 82-88.	2.1	15
460	â€“Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?â€™ A comparison between patientsâ€™ self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. <i>Aids</i> , 2001, 15, 1075-1077.	2.2	38
461	L'introduction de la PCR dans le dÃ©pistage du virus de l'hÃ©patite C dans les dons de sang : du mÃ©susage du principe de prÃ©caution.. <i>Medecine/Sciences</i> , 2001, 17, 344.	0.2	5
462	Low-Rate Emergence of Thymidine Analogue Mutations and Multi-Drug Resistance Mutations in the HIV-1 Reverse Transcriptase Gene in Therapy-Naïve Patients Receiving Stavudine plus Lamivudine Combination Therapy. <i>Antiviral Therapy</i> , 2001, 6, 179-183.	1.0	26
463	Didanosine Dosed Once Daily Is Equivalent to Twice Daily Dosing for Patients on Double or Triple Combination Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000, 24, 418-424.	2.1	3
464	Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 1041-1049.	2.2	68
465	Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients. <i>Aids</i> , 2000, 14, 517-524.	2.2	98
466	Factors predictive of disease progression and death in AIDS-related Kaposi's sarcoma. <i>HIV Medicine</i> , 2000, 1, 232-237.	2.2	10
467	Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. <i>Aids</i> , 2000, 14, 141-149.	2.2	160
468	Record-linkage between two anonymous databases for a capture-recapture estimation of underreporting of AIDS cases: France 1990-1993. <i>International Journal of Epidemiology</i> , 2000, 29, 168-174.	1.9	41

#	ARTICLE	IF	CITATIONS
469	Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy. <i>Annals of Internal Medicine</i> , 2000, 133, 401.	3.9	348
470	Rapid Progression to AIDS in HIV <sup>+</sup> Individuals with a Structural Variant of the Chemokine Receptor CX <sub>3</sub> CR1. <i>Science</i> , 2000, 287, 2274-2277.	12.6	305
471	Combined Genotypes of CCR5, CCR2, SDF1, and HLA Genes Can Predict the Long-Term Nonprogressor Status in Human Immunodeficiency Virus-1-Infected Individuals. <i>Blood</i> , 1999, 93, 936-941.	1.4	206
472	Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. <i>Aids</i> , 1999, 13, 1881-1887.	2.2	85
473	Direct HIV testing in blood donations: variation of the yield with detection threshold and pool size. <i>Transfusion</i> , 1999, 39, 1141-1144.	1.6	28
474	Risk-Benefit Analysis of Nucleic Acid Testing: The French Experience. <i>Biologicals</i> , 1999, 27, 343-348.	1.4	6
475	Timing of human immunodeficiency virus type 1 (HIV-1) transmission from mother to child: Bayesian estimation using a mixture. , 1999, 18, 815-833.		22
476	Is the AIDS incubation time changing? A back-calculation approach. , 1999, 18, 1031-1047.		9
477	Visit-driven endpoints in randomized HIV/AIDS clinical trials: impact of missing data on treatment difference measured on summary statistics. , 1999, 18, 1803-1817.		9
478	Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. <i>Journal of Medical Virology</i> , 1999, 58, 256-263.	5.0	71
479	Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. <i>Aids</i> , 1999, 13, 2075-2082.	2.2	121
480	Decreased Peripheral Circulation of HIV-Infected Cells in a Subset of Long-Term Nonprogressors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999, 21, 253.	2.1	3
481	Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism. <i>Journal of Medical Virology</i> , 1999, 58, 256-263.	5.0	10
482	Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France. <i>Neurology</i> , 1999, 53, 1197-1197.	1.1	69
483	Combined Genotypes of CCR5, CCR2, SDF1, and HLA Genes Can Predict the Long-Term Nonprogressor Status in Human Immunodeficiency Virus-1-Infected Individuals. <i>Blood</i> , 1999, 93, 936-941.	1.4	3
484	Impact of opportunistic diseases on survival in HIV-infected patients in France, 1992-1997. <i>Aids</i> , 1999, 13, 1789.	2.2	1
485	X.Pneumocystis and pneumocystosis in Europe at the end of the 20th century. <i>FEMS Immunology and Medical Microbiology</i> , 1998, 22, 87-91.	2.7	6
486	Usefulness of Pulmonary Regurgitation Doppler Tracings in Predicting In-Hospital and Long-Term Outcome in Patients With Inferior Wall Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 1998, 81, 276-281.	1.6	12

#	ARTICLE	IF	CITATIONS
487	Lack of association between human leukocyte antigens and the anti-Hu syndrome in patients with small-cell lung cancer. <i>Neurology</i> , 1998, 50, 565-566.	1.1	12
488	Apparent Enhancement of Perinatal Transmission of Human Immunodeficiency Virus Type 1 by High Maternal Anti-gp160 Antibody Titer. <i>Journal of Infectious Diseases</i> , 1998, 177, 1737-1741.	4.0	29
489	Serum Ferritin, Desferrioxamine, and Evolution of HIV-1 Infection in Thalassemic Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 18, 473-478.	0.3	56
490	Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. <i>Aids</i> , 1998, 12, 1459-1464.	2.2	186
491	Efficacy and Tolerability of Stavudine plus Lamivudine in Treatment-Naive and Treatment-Experienced Patients with HIV-1 Infection. <i>Annals of Internal Medicine</i> , 1998, 129, 525.	3.9	43
492	Decreased prevalence of intestinal cryptosporidiosis in HIV-infected patients concomitant to the widespread use of protease inhibitors. <i>Aids</i> , 1998, 12, 1395-1397.	2.2	39
493	Effect of interferon alpha on high serum androgen concentrations in HIV positive men with Kaposi's sarcoma.. <i>Journal of Clinical Pathology</i> , 1997, 50, 341-345.	2.0	3
494	Timing of mother-to-child HIV-1 transmission and diagnosis of infection based on polymerase chain reaction in the neonatal period by a non-parametric method. <i>Aids</i> , 1997, 11, 1183-1184.	2.2	47
495	Patterns of Disclosure and Perceptions of the Human Immunodeficiency Virus in Infected Elementary School-age Children. <i>JAMA Pediatrics</i> , 1997, 151, 978.	3.0	67
496	Long-Term Nonprogression in HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 16, 409-411.	0.3	7
497	Zidovudine in Patients with HIV Infection. <i>Annals of Internal Medicine</i> , 1996, 124, 372.	3.9	3
498	A prospective evaluation of clinical criteria and polymerase chain reaction assay of cerebrospinal fluid for the diagnosis of cytomegalovirus-related neurological diseases during AIDS. <i>Aids</i> , 1995, 9, 253-260.	2.2	45
499	Estimated Timing of Mother-to-Child Human Immunodeficiency Virus Type 1 (HIV-1) Transmission by Use of a Markov Model. <i>American Journal of Epidemiology</i> , 1995, 142, 1330-1337.	3.4	226
500	Hemodynamic criteria for diagnosis of right ventricular ischemia associated with inferior wall left ventricular acute myocardial infarction. <i>American Journal of Cardiology</i> , 1995, 76, 220-225.	1.6	9
501	Relations between doppler tracings of pulmonary regurgitation and invasive hemodynamics in acute right ventricular infarction complicating inferior wall left ventricular infarction. <i>American Journal of Cardiology</i> , 1995, 75, 425-430.	1.6	14
502	How much would the safety of blood transfusion be improved by including p24 antigen in the battery of tests?. <i>Transfusion</i> , 1995, 35, 542-547.	1.6	15
503	Estimation of the Size of the HIV/AIDS Epidemic due to Blood Transfusion in France. <i>International Journal of Epidemiology</i> , 1995, 24, 441-445.	1.9	4
504	Differences in androgens of HIV positive patients with and without Kaposi sarcoma.. <i>Journal of Clinical Pathology</i> , 1995, 48, 513-518.	2.0	17

#	ARTICLE	IF	CITATIONS
505	Can antiviral agents decrease the occurrence of Kaposi's sarcoma?. Lancet, The, 1995, 346, 578.	13.7	28
506	When is the epidemic warning cut-off point exceeded?. European Journal of Epidemiology, 1994, 10, 475-476.	5.7	18
507	Epidemiologic comparison of human T-lymphotropic virus type I-infected blood donors from endemic and nonendemic regions over a 3-year period. Transfusion, 1994, 34, 198-201.	1.6	6
508	Dose of desferrioxamine and evolution of HIV-1 infection in thalassaemic patients. British Journal of Haematology, 1994, 87, 849-852.	2.5	49
509	Reproducibility of non-invasive measurement and of short-term variability of blood pressure and heart rate in healthy volunteers.. British Journal of Clinical Pharmacology, 1994, 38, 109-115.	2.4	22
510	Estimation of the number of HIV-seropositive patients known to general practitioners in France. Aids, 1994, 8, 1190.	2.2	0
511	Randomized study of two doses of didanosine in children infected with human immunodeficiency virus. Journal of Pediatrics, 1993, 122, 966-973.	1.8	11
512	Cumulative incidence of HIV infection and AIDS case prediction in France. Lancet, The, 1993, 342, 436-437.	13.7	7
513	Progression to AIDS in French haemophiliacs. Aids, 1993, 7, 497-500.	2.2	52
514	Timing of mother-to-child HIV-1 transmission depends on maternal status. Aids, 1993, 7, S49-52.	2.2	53
515	A new approach to estimating AIDS incubation times: results in homosexual infected men.. Journal of Epidemiology and Community Health, 1992, 46, 582-586.	3.7	14
516	Trends in zidovudine prescription since 1987 in AIDS-free HIV-positive French patients attending university hospitals. Aids, 1992, 6, 1405.	2.2	3
517	Towards a new predictor of AIDS progression through the quantisation of HIV-1 DNA copies by PCR in HIV-infected individuals. British Journal of Haematology, 1992, 82, 467-471.	2.5	19
518	Incidence of AIDS in HIV-1 infected thalassaemia patients. British Journal of Haematology, 1992, 81, 109-112.	2.5	10
519	Epstein-Barr virus transactivator antibodies in HIV infection. Lancet, The, 1991, 338, 574.	13.7	7
520	The prevalence of diabetes mellitus in the adult population of Guadeloupe as estimated by history or fasting hyperglycemia. Diabetes Research and Clinical Practice, 1991, 12, 209-216.	2.8	18
521	A routine tool for detection and assessment of epidemics of influenza-like syndromes in France.. American Journal of Public Health, 1991, 81, 97-99.	2.7	119
522	Initiation of Insulin Treatment after 70 Years of Age: Patient Status 2 Years Later. Diabetic Medicine, 1991, 8, 773-777.	2.3	24

#	ARTICLE	IF	CITATIONS
523	A rational attitude toward serum alanine aminotransferase measurement by blood banks, based on a longitudinal study of a cohort of repeat blood donors. <i>Transfusion</i> , 1991, 31, 201-204.	1.6	1
524	SMBC in NIDDM Patients Treated by General Practitioners in France. <i>Diabetes Care</i> , 1990, 13, 454-454.	8.6	0
525	Anti-HBc Testing Can Decrease the Residual Risk of Transfusion-Related HIV Transmission by More Than One Third. <i>Vox Sanguinis</i> , 1990, 59, 248-250.	1.5	7
526	What is known about the prevention of congenital toxoplasmosis?. <i>Lancet, The</i> , 1990, 336, 359-361.	13.7	65
527	Incubation time for AIDS from French transfusion-associated cases. <i>Nature</i> , 1989, 338, 768-769.	27.8	25
528	Cell cycle models and mother-daughter correlation. <i>Journal of Theoretical Biology</i> , 1988, 131, 255-262.	1.7	18
529	The cost of diabetes in France. <i>Health Policy</i> , 1988, 9, 39-48.	3.0	19
530	Epidemiology of Toxoplasmosis among Pregnant Women in the Paris Area. <i>International Journal of Epidemiology</i> , 1988, 17, 595-602.	1.9	93
531	Incubation time for AIDS. <i>Nature</i> , 1987, 328, 582-582.	27.8	6
532	BEDSIDE ESTIMATION OF MICROALBUMINURIA. <i>Lancet, The</i> , 1986, 327, 268-269.	13.7	1
533	Rotation of the cell nucleus in living cells: a quantitative analysis. <i>Biology of the Cell</i> , 1985, 54, 135-142.	2.0	28
534	Lifelong variations in heart rates in SPF Sprague Dawley rats of both sexes. <i>Pflugers Archiv European Journal of Physiology</i> , 1979, 380, 189-195.	2.8	11